SIGA Technologies, Inc. (SIGA) Stock

SIGA Technologies, Inc. (SIGA) is a Healthcare stock trading at $4.31 (as of 2026-06-18), with a market capitalization of $335.67M and a trailing P/E of 16.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on infectious disease and health security in the United States. Its lead product, TPOXX, is an oral antiviral formulation for treating human smallpox caused by variola virus, and it also participates in a partnership with Cipla Therapeutics for antibacterial drugs primarily addressing biothreats.

Valuation — source: SEC EDGAR (first-party)
Price$4.31
Market Cap$335.67M
P/E Ratio16.7
EV / EBITDA9.0
Price / Book2.21
Price / Sales3.58
Dividend Yield12.9%
DCF Value (model)$17.47
DCF Upside vs Price305.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$94.57M
Net Margin24.6%
Return on Equity13.3%
Current Ratio3.25
Revenue Growth (YoY)-11.3%
EPS Growth (YoY)400.0%
Financial Health — source: SEC EDGAR
Altman Z-Score10.55 (safe)
Valuation vs Sector & Industry
Stock P/E16.7
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-20.0%
vs Industry-1.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($18.69M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODiem Nguyen
Employees46
CountryUS
IPO Date1997-09-10

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • PepGen Inc. (PEPG)
  • Solid Biosciences Inc. (SLDB)
  • ADC Therapeutics S.A. (ADCT)
  • Monopar Therapeutics Inc. (MNPR)
  • Evolus, Inc. (EOLS)
  • 4D Molecular Therapeutics, Inc. (FDMT)
  • DiaMedica Therapeutics Inc. (DMAC)
  • Akebia Therapeutics, Inc. (AKBA)
SIGA earnings history · SIGA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.